Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of MT-2990 in healthy male volunteers
NL-OMON45915Phase 1Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT-2990 in Inflammatory Disorders (6 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Adverse events, Vital signs and 3 more. Started May 2017; status: active, not recruiting.
02
Drugs
MT-2990
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NL-OMON45915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45915.